Abiomed, Inc. (ABMD)
| Market Cap | 15.98B |
| Revenue (ttm) | 935.26M |
| Net Income (ttm) | 154.41M |
| Shares Out | 45.31M |
| EPS (ttm) | 3.38 |
| PE Ratio | 104.13 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,834 |
| Open | 349.45 |
| Previous Close | 349.68 |
| Day's Range | 346.24 - 353.77 |
| 52-Week Range | 242.73 - 387.40 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 387.33 (+10.0%) |
| Est. Earnings Date | Oct 28, 2021 |
About ABMD
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous ...
Financial Performance
In 2020, Abiomed's revenue was $847.52 million, an increase of 0.79% compared to the previous year's $840.88 million. Earnings were $225.53 million, an increase of 11.09%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for Abiomed stock is "Buy." The 12-month stock price forecast is 387.33, which is an increase of 9.98% from the latest price.
News
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.
Earnings Preview: Abiomed (ABMD) Q2 Earnings Expected to Decline
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed second quarter fiscal 2022 earnings and conference call notification.
Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?
Abiomed (ABMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
2 Hot Stocks to Buy and Hold Until You Retire
They have strong products and high financial performance.
Abiomed (ABMD) Up 6% Since Last Earnings Report: Can It Continue?
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?
Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag
Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.
Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag
The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the Impella ECP heart pump to be compatible with smal...
FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump
DANVERS, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Abiomed (ABMD) Beats Q1 Earnings and Revenue Estimates
Abiomed (ABMD) delivered earnings and revenue surprises of 3.77% and 3.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $253 million, up 53% year over year.
Abiomed (ABMD) Reports Next Week: Wall Street Expects Earnings Growth
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.
Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financial results for the first quarter of the fiscal year 2022 on Thursday, August 5, 2021.
Could This Recently IPOed Medical Device Maker Make You Rich?
Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed's (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe...
Abiomed (ABMD) Enters Overbought Territory
Abiomed (ABMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for ...
Here's Why Abiomed Stock Is Attractive After A 20% Drop
The stock price of Abiomed , a medical devices company best known for Impella, the world's smallest heart pump, looks attractive at current levels of $280, despite it being up 2x from the levels of $132...
Abiomed to Present at Upcoming Investor Conferences
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at William Blair's 41st Annual Growth Stock Conference and the Jefferies Virtual Healthcare Conference.